Gonalef filed for female infertility in Japan
This article was originally published in Scrip
Executive Summary
Merck Seronohas submitted an approval application in Japan for the recombinant human follicle-stimulating hormone product Gonalef (follitropin alfa) for the additional indication of induction of ovulation in infertile women. The filing includes data from a local Phase III study in women with no or irregular ovulation or polycystic ovary syndrome. Gonalef (also marketed elsewhere as Gonal-f) was first launched in Japan in 2006 for infertility in men with hypogonadotropic hypogonadism, for which it is used in combination with human chorionic gonadotropin.
You may also be interested in...
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Teva’s immunology biosimilar launches; Intra-Cellular’s promising depression data; Phase III sleep apnea win for Lilly’s tirzepatide; an interview with Viking’s CEO; and China looks to define innovative drugs.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.